LONDON and NEW YORK, March 19, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and for inflammatory eye diseases, today announced it has been informed that John Brancaccio, Non-Executive Director, has acquired 5,000 of the Company’s ordinary shares on NASDAQ at $1.61, bringing his total holding to 31,201 shares. About Urcosimod (formerly called OK-101) Urcosimod is ...

Core Viewpoint - OKYO Pharma Limited is advancing its clinical-stage biopharmaceutical development, particularly focusing on therapies for neuropathic corneal pain and inflammatory eye diseases, with recent positive trial results for its lead drug, Urcosimod [1][2][3]. Group 1: Company Developments - Gary Jacob, Chief Development Officer and Director of OKYO Pharma, has acquired 30,980 ordinary shares at $1.59, increasing his total holdings to 108,920 shares [1]. - OKYO Pharma has successfully completed a Phase 2 trial for Urcosimod, demonstrating its efficacy in reducing neuropathic corneal pain [3]. - The company plans to initiate a Phase 2b/3 multiple-dose study involving approximately 150 subjects to further evaluate Urcosimod for treating neuropathic corneal pain in the first half of the year [3]. Group 2: Product Information - Urcosimod, previously known as OK-101, is a lipid-conjugated chemerin peptide agonist targeting the ChemR23 receptor, which is involved in the inflammatory response in the eye [2]. - In a randomized, placebo-controlled, double-masked Phase 2a trial with 18 subjects, Urcosimod showed significant pain reduction for neuropathic corneal pain [2]. - The drug has also demonstrated positive results in a prior Phase 2 trial involving 240 subjects for dry eye disease, supporting its development for neuropathic corneal pain [2].

Company Overview - Proactive is a financial news publisher that provides fast, accessible, informative, and actionable business and finance news content to a global investment audience [2] - The company has a team of experienced news journalists who produce independent content across various financial markets [2] Market Focus - Proactive specializes in medium and small-cap markets while also covering blue-chip companies, commodities, and broader investment stories [3] - The news team delivers insights across multiple sectors, including biotech and pharma, mining and natural resources, battery metals, oil and gas, crypto, and emerging digital and EV technologies [3] Technology Adoption - Proactive is committed to adopting technology to enhance its content creation and workflow processes [4] - The company utilizes automation and software tools, including generative AI, while ensuring that all published content is edited and authored by humans [5]

LONDON and NEW YORK, March 18, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and for inflammatory eye diseases, today announced new positive findings from an exploratory analysis of patient-reported outcomes in its recently completed Phase 2a trial of urcosimod (0.05%) for the treatment of NCP. This new quality-of-life (QoL) data will be presented at the Associat ...

Core Viewpoint - OKYO Pharma Limited announced the acceptance of its abstract for presentation at the ARVO 2026 Annual Meeting, highlighting the positive results of its Phase 2a clinical trial for urcosimod, a treatment for neuropathic corneal pain (NCP) [1][4]. Group 1: Clinical Trial Results - The Phase 2a clinical trial of urcosimod demonstrated clinically meaningful pain reduction and quality-of-life improvement in NCP patients, as measured by the Visual Analogue Scale (VAS) [2][3]. - Urcosimod showed potential to help restore corneal nerve structure in patients suffering from NCP [2]. Group 2: Drug Development and Regulatory Status - Urcosimod is the first candidate to receive IND clearance specifically for NCP and has been granted FDA Fast Track designation [3][5]. - Following the positive Phase 2a results, the company plans to initiate a larger multicenter Phase 2b/3 trial involving approximately 150 patients to further evaluate urcosimod's efficacy and safety [3][5]. Group 3: Company Overview - OKYO Pharma is a clinical-stage biopharmaceutical company focused on developing innovative therapies for NCP and inflammatory eye diseases, with its shares listed on the Nasdaq Capital Market [9]. - The company aims to discover and develop novel molecules to treat NCP and other ocular diseases, having recently completed a successful Phase 2 trial of urcosimod [9].

About this content About Emily Jarvie Emily began her career as a political journalist for Australian Community Media in Hobart, Tasmania. After she relocated to Toronto, Canada, she reported on business, legal, and scientific developments in the emerging psychedelics sector before joining Proactive in 2022. She brings a strong journalism background with her work featured in newspapers, magazines, and digital publications across Australia, Europe, and North America, including The Examiner, The Advocate, ...

About this content About Angela Harmantas Angela Harmantas is an Editor at Proactive. She has over 15 years of experience covering the equity markets in North America, with a particular focus on junior resource stocks. Angela has reported from numerous countries around the world, including Canada, the US, Australia, Brazil, Ghana, and South Africa for leading trade publications. Previously, she worked in investor relations and led the foreign direct investment program in Canada for the Swedish government ...

Core Viewpoint - OKYO Pharma Limited has announced a public offering of 10,815,000 ordinary shares at a price of $1.85 per share, aiming to raise approximately $20 million before expenses and discounts [1][2]. Group 1: Offering Details - The gross proceeds from the offering are expected to be around $20 million, with the potential to increase to approximately $23 million if the underwriter fully exercises its option to purchase additional shares [2]. - The offering is managed solely by Piper Sandler & Co., and is expected to close around February 17, 2026, pending customary closing conditions [3]. Group 2: Use of Proceeds - The net proceeds from the offering will primarily be used for clinical development of product candidates, general corporate purposes, and working capital [2]. Group 3: Company Overview - OKYO Pharma is a clinical-stage biopharmaceutical company focused on developing therapies for neuropathic corneal pain (NCP) and inflammatory eye diseases, with shares traded on the Nasdaq Capital Market [6]. - The company has recently completed a successful Phase 2 trial of its lead drug, urcosimod, for NCP and plans to initiate a Phase 2b/3 study involving approximately 150 subjects in the first half of the year [6].

Company Overview - OKYO Pharma Limited is a clinical-stage biopharmaceutical company focused on developing therapies for neuropathic corneal pain (NCP) and inflammatory eye diseases [5] - The company is listed on the Nasdaq Capital Market and is dedicated to discovering and developing novel molecules for treating ocular diseases [5] Offering Details - The company announced an underwritten public offering of its ordinary shares, with all shares to be sold by the company [1] - The underwriter, Piper Sandler & Co., will have a 30-day option to purchase up to an additional 15% of the shares sold at the public offering price [1][2] - The net proceeds from the offering will primarily be used for clinical development of product candidates, general corporate purposes, and working capital [2] Clinical Development - OKYO recently completed a successful Phase 2 trial of its flagship drug, urcosimod, in patients with NCP [5] - The company plans to initiate a Phase 2b/3 multiple-dose study of urcosimod, targeting approximately 150 subjects in the first half of the year [5] Regulatory Information - The securities are being offered under a shelf registration statement filed with the U.S. Securities and Exchange Commission (SEC) [3] - A preliminary prospectus supplement describing the terms of the offering has been filed with the SEC and is available on their website [3]

Core Viewpoint - OKYO Pharma has appointed Leerink Partners as the new sales agent for its At-The-Market (ATM) equity offering, transitioning from B. Riley Securities, to enhance its financial flexibility and support ongoing clinical development [2][3][4]. Group 1: Appointment of Sales Agent - OKYO Pharma Ltd has transitioned its ATM equity offering facility to Leerink Partners, replacing B. Riley Securities as the exclusive sales agent [2][3]. - Leerink Partners will facilitate the sale of common shares directly into the market at prevailing prices, depending on market conditions and company discretion [3]. Group 2: Purpose and Benefits of ATM Facility - The ATM facility is designed to provide OKYO Pharma with the flexibility to raise capital opportunistically while minimizing market disruption [4]. - The CFO of OKYO Pharma emphasized that this transition enhances financial flexibility to support ongoing clinical development and corporate objectives without committing to a fixed equity raise [5]. Group 3: Financial Terms - Leerink Partners will receive a commission of 3% of gross proceeds from any shares sold under the ATM program [6].